Jyong Biotech Ltd. Ordinary Shares
MENS | NASDAQ
$1.91
+$0.03 (+1.60%)
Nov 2, 2026, 9:31 AM ET · Market open
Company Profile
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
Key Executives
| Name | Position |
|---|---|
| Fu-Feng Kuo | Chief Executive Officer & Chairwoman of the Board |
| Fenglin Hsu | Chief Technology Officer & Director |
| Wei Zhang | Chief Financial Officer |
| Wanwen Su | Chief Science Officer |
Jyong Biotech Ltd. Ordinary Shares
| Country | Taiwan |
| IPO Date | Jun 17, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Fu-Feng Kuo |
Contact Details
23F‑3, No. 95, Section 1, Xintai 5th Road New Taipei City,
TP 221 Taiwan
Stock Details
| Ticker Symbol | MENS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001954488 |
| CUSIP Number | G83116106 |
| ISIN Number | KYG831161065 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove MENS